Human Leukocyte Antigens class II (HLA II) gene profile from an admixed population of patients with type 1 diabetes with severe diabetic retinopathy: a nested case-control study in Brazil.
HLA
Human leukocyte antigen
Retinopathy
Type 1 diabetes
Journal
Diabetology & metabolic syndrome
ISSN: 1758-5996
Titre abrégé: Diabetol Metab Syndr
Pays: England
ID NLM: 101488958
Informations de publication
Date de publication:
06 Aug 2021
06 Aug 2021
Historique:
received:
08
05
2021
accepted:
28
07
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
8
8
2021
Statut:
epublish
Résumé
Although the well-established role of the HLA genes on the predisposition of type 1 diabetes (T1D), its contribution to the development and progression of diabetic retinopathy is still unclear, especially in admixed populations. We aimed to study the relationship between HLA alleles and severe diabetic retinopathy in a highly admixed population of T1D patients. This was a nested case-control study based on a cross-sectional, nationwide survey conducted in Brazil. We included 117 patients with severe diabetic retinopathy and 117 random controls composed of T1D patients without retinopathy, matched for diabetes duration. HLA-class II genes (HLA-DRB1, -DQA1, and -DQB1) were genotyped using the SSO and NGS methods. Haplotypes HLA-DRB1*04:05 ~ DQA1*03:01 g ~ DQB1*03:02 (OR 1.75, CI 0.97-3.16, p value 0.058) and HLA-DRB1*13:02 ~ DQA1*01:02 ~ DQB1*06:04 (OR 5.18, CI 1.12-23.09, p value 0.019) were more prevalent on the severe DR group but they did not present statistically difference after Bonferroni correction. The most frequent haplotype on both groups was HLA-DRB1*03:01 ~ DQA1*05:01 g ~ DQB1*02:01 (29.6% on severe DR and 33.33% on the control group). Our study showed no influence of HLA genes on the development of DR. Further longitudinal data is needed to better understand the role of genetic factors on this multifactorial significant microvascular complication.
Sections du résumé
BACKGROUND
BACKGROUND
Although the well-established role of the HLA genes on the predisposition of type 1 diabetes (T1D), its contribution to the development and progression of diabetic retinopathy is still unclear, especially in admixed populations. We aimed to study the relationship between HLA alleles and severe diabetic retinopathy in a highly admixed population of T1D patients.
METHODS
METHODS
This was a nested case-control study based on a cross-sectional, nationwide survey conducted in Brazil. We included 117 patients with severe diabetic retinopathy and 117 random controls composed of T1D patients without retinopathy, matched for diabetes duration. HLA-class II genes (HLA-DRB1, -DQA1, and -DQB1) were genotyped using the SSO and NGS methods.
RESULTS
RESULTS
Haplotypes HLA-DRB1*04:05 ~ DQA1*03:01 g ~ DQB1*03:02 (OR 1.75, CI 0.97-3.16, p value 0.058) and HLA-DRB1*13:02 ~ DQA1*01:02 ~ DQB1*06:04 (OR 5.18, CI 1.12-23.09, p value 0.019) were more prevalent on the severe DR group but they did not present statistically difference after Bonferroni correction. The most frequent haplotype on both groups was HLA-DRB1*03:01 ~ DQA1*05:01 g ~ DQB1*02:01 (29.6% on severe DR and 33.33% on the control group).
CONCLUSIONS
CONCLUSIONS
Our study showed no influence of HLA genes on the development of DR. Further longitudinal data is needed to better understand the role of genetic factors on this multifactorial significant microvascular complication.
Identifiants
pubmed: 34362434
doi: 10.1186/s13098-021-00702-y
pii: 10.1186/s13098-021-00702-y
pmc: PMC8344141
doi:
Types de publication
Journal Article
Langues
eng
Pagination
83Subventions
Organisme : Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
ID : E-26/110.170/2013
Organisme : Conselho Nacional de Desenvolvimento Científico e Tecnológico
ID : 563753/2010-2
Informations de copyright
© 2021. The Author(s).
Références
Diabetologia. 1993 Dec;36(12):1293-8
pubmed: 8307258
Clin J Am Soc Nephrol. 2009 Nov;4(11):1832-43
pubmed: 19820136
Int Ophthalmol. 1985 Apr;8(1):33-5
pubmed: 3860483
Am J Ophthalmol. 1986 Dec 15;102(6):693-700
pubmed: 3789049
Rev Assoc Med Bras (1992). 2009 May-Jun;55(3):268-73
pubmed: 19629344
Diabetologia. 1996 Nov;39(11):1313-7
pubmed: 8932997
Sci Rep. 2017 Mar 06;7:43513
pubmed: 28262800
Diabetes. 2019 Feb;68(2):241-247
pubmed: 30665952
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
JAMA Ophthalmol. 2014 Jan;132(1):96-107
pubmed: 24201651
Eur J Immunogenet. 1999 Oct;26(5):361-72
pubmed: 10553503
Diabetes Res Clin Pract. 2017 Dec;134:44-52
pubmed: 28951342
Diabetes Care. 2016 Sep;39(9):1643-9
pubmed: 27555623
Diabetes. 2008 Apr;57(4):1084-92
pubmed: 18252895
Diabetes. 1992 Jul;41(7):879-85
pubmed: 1612203
Acta Diabetol. 2020 Aug;57(8):937-945
pubmed: 32125531
J Diabetes Res. 2015;2015:694107
pubmed: 26539552
Ophthalmology. 2003 Sep;110(9):1677-82
pubmed: 13129861
Sci Rep. 2020 Apr 20;10(1):6628
pubmed: 32313169
Diabetes Care. 2014;37(1):9-16
pubmed: 24356592
Clin Exp Immunol. 1999 Mar;115(3):409-14
pubmed: 10193411
Hum Mol Genet. 2011 Jun 15;20(12):2472-81
pubmed: 21441570
Front Physiol. 2016 Jun 01;7:200
pubmed: 27313539
Lancet. 1974 Nov 9;2(7889):1153
pubmed: 4139464
Diabetes. 1982 Mar;31(3):226-31
pubmed: 6818073
Genet Epidemiol. 1989;6(1):143-8
pubmed: 2499501
Curr Diab Rep. 2011 Dec;11(6):533-42
pubmed: 21912932
BMC Public Health. 2018 Aug 8;18(1):989
pubmed: 30089461
Mol Ecol Resour. 2010 May;10(3):564-7
pubmed: 21565059
Mol Biol Evol. 1995 Sep;12(5):921-7
pubmed: 7476138
J Diabetes Complications. 1997 Jul-Aug;11(4):203-7
pubmed: 9201596
Diabetol Metab Syndr. 2015 Dec 21;7:116
pubmed: 26697120
Hum Immunol. 2013 May;74(5):538-44
pubmed: 23376458
Pediatr Diabetes. 2018 May;19(3):346-353
pubmed: 29094512
Biometrics. 1992 Jun;48(2):361-72
pubmed: 1637966
Ophthalmology. 2002 Feb;109(2):275-81
pubmed: 11825808